Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Drano - "That said, why did the price just take a dive?"
Answer - So that I can buy more shares under $2
An orderly rise while the RSI stays under 70 or so would be ideal. That said, it's highly unlikely to happen that way. If the market yawns at this news and the sp doesn't move up, we are at least seeing a solid base built at the $2 level. WHo among you would not have taken that a year ago?
$2 gives us AMEX potential. But all the talk about uplisting so far is (IMHO) just speculation. I have not read anything firm about actions taken to uplist by the company.
Some publicity beyond the long-term touts would also be beneficial.
The PR is a pretty clear indication that NNVC now has the best treatment available for Dengue. The same thing is likely true for HIV, FLU, Herpes and many other virus borne diseases. No hints at toxicity.
Let's get that IND going. There are sick people waiting.
IMHO: Calling Dr. Harris (or any of the others involved in testing NNVC drug candidates) is pointless. I think much of the communication with Dr. Seymour is also a waste of time, as he can't really say anything new to us either.
If any of us knew for CERTAIN about significant news, the sp would be over $3 right now.
I am pretty sure there was profit taking Friday late, plus some flat out price manipulation on very little volume. I was very close to a partial cash-in myself...25% in less than 2 weeks is hard to turn away from. However, significant news next week will trump the doji.
I think I'll just hold. There's no technical reason to sell and Monday looms large. We have to remember the last 2 announcements were on Tuesday.
The trading is all just garbage now...100 shares here and there, walking the price down
Going to hold everything for Monday's big announcement, but I am tempted to hedge...the $ from those $1.60 shares from last week looks tempting
ahhhh....and HERE WE GO! 2.03 and climbing
i'm no canadian hey....i'm set up with NNVC in both IRA tax-deferred and "regular" accts. Don't have a Roth, though.
thanks....I'll look into it
I would like to know more about that type of account,,.../.
Where are all those who thought the Seaside agreement was so bad? I can't believe no one (other than me) is comparing it to the ARWR deal.
Compare the Seaside deal with Arrowhead's new financing....and take a look at what happened to the share price of ARWR yesterday.
"Arrowhead Research Corp. (ARWR) said it will sell $8.7 million in stock and warrants as the development-stage nanotechnology company raises funds for new investments and operating expenses.
Shares slumped on the news and were recently down 27% to $1.19.
The company, which is focused on the electronics and biotech industries, said it would sell 6.6 million units consisting of one share and a five-year warrant to buy one-half share at 82.5 cents. There are about 63 million shares outstanding and the units are being sold for $1.31 each. "
This was done with a sp averaging $1.70 over the last month. The Seaside arrangement looks pretty good....
Got it. DUH....having a slow morning mentally I guess
Doctor F: "there may come a recognition that DengueCide is the only thing in development that is promising"
That is a scary thought! What in the world prompted that comment?
Some folks obviously believe something's about to happen
The report's key point is "GET IN NOW"
Hard to evaluate the report given no new info. from the company. I continue to agree with the analysis, but the basic analysis is the same as before.
RSI, Hammer, 50dma, etc, etc, etc, they all are good buy/sell indicators. What is often the most difficult is to ACTUALLY DO what is indicated... ignoring emotion, advice from others, the hot tip on Investor's Hub, etc.
You raise an interesting point...could take some profit here. Hmmm?
something good!
Check my Friday post...I am so happy I loaded back up last week. Now I can say I was ready for this and I'm loving it.
I posted this Sunday:
"Another key to a turnaround in SP is capitulation, which IMO works on both the overall market and individual stocks. For stocks like NNVC, when long-time shareholders (this means you)start getting ornery, look for a bottom."
Capitulation is not just by bears, IMO. It's when everyone is ready to throw in the towel...volume shrinks, interest and talk wanes. This is exactly what happened over the last couple of days.
Now let's see if we can get a sustained rally going.
What is the reason for today's increase? It could just be a couple of buyers!
Thanks Makem, I'm with you.
*MULTI-LEVEL CYNICISM*
"Nanoviricides to Stop BP OIL Leak; President approves $10 billion advance."
So they stop the oil leak, then what? Where's the revenue stream? Seaside will just play it to their advantage. The Docs will just bank all the money for themselves, and we'll still be stuck with oil on our hands. Not to mention the liability! I don't think I like this stopping the oil leak business. It looks to be a play by the shorts to take down the SP.
A bit of levity for Sunday Night.
The 50DMA is a key. I just wish I had the discipline to follow it all of the time. That said, an UNEXPECTED PR will move the SP. There has not been anything unexpected for some time.
Another key to a turnaround in SP is capitulation, which IMO works on both the overall market and individual stocks. For stocks like NNVC, when long-time shareholders (this means you)start getting ornery, look for a bottom.
This week I've been a buyer. Next week I'm a cheerleader. Gimme an I, an N, and a D:
Investigative
New
Drug
I like the TA! Maybe need to buy some today?
If Seaside were to sell all the shares every two weeks, that selling pressure would be about 20% over "normal". That much seems clear.
I hope you are right. $20 would be good, even if it is pretty far down the road. I'm not sure NNVC will still exist a few years down the road...it will either succeed and be purchased or, well, I guess not succeed is the way to state it.
*COMMENT ON SHARE PRICE* At $1.60, some were arguing the stock was overvalued. A while back at $2.40 (with and RSI near 80), much of the talk was "to the moon, Alice!"
The weird price action looks very suspicious, with bid over ask and trades well above ask and below bid. But real news trumps all of that.
Who knows? I'm just sitting still and waiting to see the next news.
*NEWS*
NanoViricides Reports that Antiviral Efficacy was Demonstrated Against Two Different HIV-1 Isolates in Cell Culture Studies, Corroborating Previous Findings in Animal Studies
0 minutes ago - Businesswire
Related Companies
Symbol Last %Chg
NNVC 1.54 0.00%
As of 3:59 PM ET 6/7/10
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.
This in vitro or cell culture study validated the in vivo anti-HIV activity of the nanoviricides(R) as determined in a SCID/hu Thy/Liv mouse model by KARD Scientific, a contract research organization, and previously reported by the Company.
Significantly, a subset of the anti-HIV nanoviricides tested in cell culture models at Southern Research had very similar activity against two distinctly different isolates of HIV-1, viz. Ba-L and IIIB. The Company had designed the ligands using reported gp120 structures of several HIV-1 strains.
The HIV-1 isolate Ba-L was the same as that employed in the Company's previously reported animal model studies. This virus binds and infects cells expressing the human receptor CCR5 in addition to the well known receptor CD4. In contrast, HIV-1 IIIB is a CXCR4-tropic virus that infects cells expressing the human receptor CXCR4 in addition to the receptor CD4. The same viral gp120 or SU glycoprotein is involved in binding to both co-receptors, viz. CD4 and either CCR5 or CXCR4. HIV that binds to CD4 and to at least one other co-receptor, such as CXCR4 or CCR5, results in productive infection leading to disease, and eventually AIDS.
It has been a formidable challenge for researchers in the field to develop an anti-HIV drug that works against all subtypes and strains. Several anti-HIV drugs and drug candidates have demonstrated significant activity against only one of these various HIV-1 subtypes. In addition, HIV mutates, changing its genome and protein structure during an active infection. Mutants resistant to the patients' treatment drugs can develop and proliferate, leading to failure of therapy, including the HAART regimen.
"We believe that our strategy of designing ligands that are close mimics of the invariant binding site on CD4 has resulted in nanoviricides that are active against multiple HIV-1 subtypes," said Anil R. Diwan, PhD, President of the Company, adding, "The results of the Southern Research study suggest that mutations in HIV-1 may be unlikely to result in significant resistance to an anti-HIV nanoviricide."
The Company had provided Southern Research with a panel of seventeen substances, including active and inactive substances. The Southern Research study was performed three different times on the same set of materials with substantially consistent results. The results confirmed that the previously demonstrated in vivo anti-HIV activity of certain nanoviricides was correlated with their in vitro anti-HIV activity.
The Company has previously reported that several of its nanoviricide drug candidates were more than 25 times (2,500%) superior to a three-drug HAART cocktail in a standard SCID-hu Thy/Liv mouse model study of HIV-I infection. In particular, treatment with only 150 mg/kg nanoviricides, as opposed to 4,200 mg/kg HAART drug cocktail (i.e. 28 times greater total dosage of HAART cocktail) resulted in viral load decrease that was equal to or better than HAART, and increased double-positive CD4+/CD8+ T cell counts that were equal to or better than HAART. The nanoviricides were equal or superior to the HAART cocktail in all parameters evaluated. Significantly, the nanoviricide treatment was given only during the first week in this six-week anti-HIV study, whereas HAART treatment was continued daily.
"We are now a step closer to filing a pre-IND application for HIVCide(TM) with the US FDA," said Eugene Seymour, MD, MPH, CEO of the Company.
bid 1.60 ask 1.55 last 1.53
You have got to be kidding me.
I'm out.
All quiet on the PR front at 7am.
So, are we 45 minutes from a nice PR, or waiting in vain for a SP turnaround?
The market obviously is unimpressed by the results. I would find it very odd if tomorrow were up significantly on no other news. On the other hand, this drop is going to represent a buying opportunity. The question is ... at what price?
That seems likely. We'll have to wait and see.
The lack of specific data does NOT bother me. Everyone agrees on "Signicicant Efficacy", which is more important than "99%" or some other number. Especially when "99%" is likely not good enough! "Significant Efficacy" means the treatment worked. Period. And the PR means that all parties involved agree that it worked. Ok. Great, even. Now let's move on to the next stage.
At this point I'm pretty sure the SP won't move that much. This isn't a pump and dump. Results were expected and now they are coming. First result is positive.
*NEWS* NanoViricides Reports that Significant Efficacy was Achieved in Initial Studies on Dengue Virus
Now this should begin to move the price back up!